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PoolingHeterogenous subtypes of breast cancer need to be analyzed separately. Pooling of datasets can provide reason-
able sample sizes but dataset bias is an important concern. We assembled a combined dataset of 579 Affymetrix
microarrays from triple negative breast cancer (TNBC) in Gene Expression Omnibus (GEO) series GSE31519. We
developed amethod for selecting comparable datasets and to control for the amount of dataset bias of individual
probesets.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).SpeciﬁcationsOrganism/cell line/
tissueHomo sapiens/breast tumor tissueSex Female
Sequencer or array
typeAffymetrix GeneChip HG-U133A and HG-U133PLUS2Data format Raw data: CEL ﬁles, normalized data: MAS5 Log2
magnitude-normalizedExperimental
factorsPrimary dataset origin of samplesExperimental
featuresSelection of comparable datasets and control for dataset
bias of each probesetConsent Publicly available data from Gene Expression Omnibus
(GEO) databaseSample source
locationNADirect link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31519
(link to GEO Series)
http://www.ncbi.nlm.nih.gov/geo/download/?acc=
GSE31519&format=ﬁle&ﬁle=rics and Gynecology, Goethe
rt, Germany.
. This is an open access article underGSE31519%5Fcomplete%5Fdataset%2Etxt%2Egz (direct link to
normalized complete dataset in GEO supplement)
http://www.ncbi.nlm.nih.gov/geo/download/?acc=
GSE31519&format=ﬁle&ﬁle=
GSE31519%5FTNBC%5FSampleInfo%5FBCR%2Etxt%2Egz (direct link
to sample information in GEO supplement).
Experimental design, materials and methods
Background
Breast cancer is a heterogeneous disease of different subtypes and
separate analyses by subtype are mandatory. Triple negative breast
cancer (TNBC) represents an aggressive disease and the use of currently
available molecular prognostic signatures is limited. Reasonable sample
sizes of TNBC formolecular analysesmay be obtained by pooling several
microarray datasets. However, because of signiﬁcant inter-laboratory
variation such studies require precise control of dataset bias.Dataset
The set of 579 TNBCs in GSE31519 includes: (i) 67 CEL ﬁles in
GSE31519 (GSM782523–GSM782589), (ii) 489 re-analyzed GEO sam-
ples linked in GSE31519, and (iii) 23 re-analyzed ArrayExpress samples.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Selection of the TNBC ﬁnding cohort from multiple datasets based on dataset
comparability. Triple negative breast cancers (TNBCs, n = 579) from 28 datasets were
sorted by dataset according to a dataset comparability metric (horizontally). Shown are
the full array data of normalized Affymetrix U133A microarrays. The 15most comparable
datasets encompassing n=394 TNBC sampleswere subsequently used as aﬁnding cohort
and the remaining 13 datasets (n = 185 TNBC samples) were withheld as a validation
cohort.
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Fig. 2. Analysis of dataset bias among probesets. A) The standard Kruskal–Wallis rank test
was used to analyze the dependence of each individual probeset's expression on the
vector of the 15 different datasets in the ﬁnding cohort of n = 394 samples. The distribu-
tion of the rank sum statistics for all 22,283 probesets from the U133A array is shown.
B) Distribution of the Kruskal–Wallis rank sum statistics among the 12 biased probesets
of the hemoglobin metagene.
355T. Karn et al. / Genomics Data 2 (2014) 354–356MAS5 values were taken from GEO if available. For samples with no
MAS5 values, CEL ﬁleswere downloaded fromGEO and the affy package
[1] from Bioconductor [2] was used to generate MAS5 values. Next,
MAS5 values corresponding only to the 22,283 probesets from the
U133A array were compiled. Subsequently, normalization of MAS5
data was performed using the command line version of the program
CLUSTER 3.0 (Michael Eisen; updated by Michiel de Hoon; http://
bonsai.hgc.jp/~mdehoon/software/cluster/command.txt).
The following three steps were performed in the following order:
1. log2 transformation of MAS5 values
2. median centering of arrays
3. magnitude normalization of arrays.
These three steps correspond to the following commands:
cluster.com ﬁlename -l
cluster.com ﬁlename -ca m
cluster.com ﬁlename -na
In step 3 of these procedures (magnitude normalization) the expres-
sion values of all (22,283) probesets from the U133A array are multi-
plied by a scale factor S so that the magnitude (sum of the squares of
the values) equals one. The resulting dataset was used for the subse-
quent analyses. The normalized data are available under the following
link:
http://www.ncbi.nlm.nih.gov/geo/download/?acc=
GSE31519&format=ﬁle&ﬁle=
GSE31519%5Fcomplete%5Fdataset%2Etxt%2Egz
All 579 samples in the dataset are triple negative according to the
following predeﬁned cutoffs [3] for ESR1 (205225_at) b 0.0075, PGR
(208305_at) b−0.0078, and HER2 (216836_s_at) b 0.0135.
An R script of the subsequent analysis is available in the Supplemen-
tary data.
Analyses
A major concern of the pooling procedure are systematic technical
differences between individual datasets (“batch effects”). Many adap-
tion methods as e.g. Z-normalization often do not eliminate but rather
blur such effects. Thus we applied two further strategies to cope with
this problem. First, we selected only highly comparable datasets for
our ﬁnding cohort. Second, we controlled for biased genes which still
show associations with the dataset vector. These two strategies are
described below.
Comparability of datasets
The 579 arrays came from 28 different datasets. We calculated a
comparability metric C for each of the datasets to identify the most
comparable samples. This metric C is derived from the sum of the
squared differences of the mean (μ) within a speciﬁc dataset and
among all datasets, respectively, normalized by the standard deviation
(σ) calculated for all genes (g) on the array:
Cdataseti ¼
Xn
g¼1
μg;dataseti−μg;total
σg;total
 !2
:
The metric is based on the assumption that overall the mean of a
gene expression within a dataset should be similar between different
datasets and gives an estimation to what extent the arrays in a speciﬁc
dataset differ from the combined overall cohort. Larger datasets will
dominate because of their higher impact on the global mean. All
datasets were sorted according to this metric and the top 15 datasets
with the lowest values (normalized C ≤ 0.03), corresponding to 394
samples in total, were used as the discovery cohort (Fig. 1).Control for biased probesets
All probesets were checked for dataset bias (i.e. differential expres-
sion by dataset of origin thatwould indicate laboratory-bias or sampling
356 T. Karn et al. / Genomics Data 2 (2014) 354–356differences compared to the rest). To assess dataset bias, we used
Kruskal–Wallis statistic comparing the expression of each probeset
with the primary dataset vector across the 394 TNBCs. Each probeset
was then taggedwith that Kruskal–Wallis value throughout all analyses.
Thus an enrichment of biased probesets can bemonitored in any down-
stream application e.g. cluster analyses [4–6]. Cutoffs for exclusion of
probesets due to strong dataset bias may be derived from the distribu-
tion of the Kruskal–Wallis statistic over all probesets. Fig. 2 demon-
strates the enrichment of biased probesets in the hemoglobin
metagene reported in [4]. This effect originated from the inclusion of
two datasets which were obtained from ﬁne needle aspiration (FNA)
samples. Such samples generally contain relatively higher amounts of
blood and lower amounts of stromal tissue as compared to surgical
biopsy samples.
Acknowledgements
This work was supported by grants from the H.W. & J. Hector-
Stiftung, Mannheim (grant number: M67).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2014.09.014.References
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